Late September placing?4 Jul 2019 18:56
As has been kindly shared by ValJu, Valirx's cash burn in now under £100k per month and on that basis they will have 6 months funding once they finalised the sale of the unlisted asset (? we do not know what the asset is) and receive the R&D tax credit.
The reduced cash burn makes sense as they are no longer providing funds to Valiseek - the RNS dated 26 March 2019 stated: 'Whilst ValiRx currently holds a 55.5 per cent. majority equity ownership of ValiSeek, the Company does not have any further financial and contractual requirements or commitments towards the remaining stages of ValiSeek's clinical development.'
In the event that there is no news about other financing sources there will inevitably be a need to raise more funds and I expect that it will be prudent to do so before Halloween and the implications of a possible hard Brexit on raising funds in an uncertain environment.
Of course, taking a geopolitical and macroeconomic approach to fundraising is hardly an exact science.